Breaking News, Collaborations & Alliances

Gliknik Receives $15M Milestone from Pfizer

Follows start of Phase 1 trial for Pfizer candidate PF-06755347

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gliknik Inc. will receive a $15 million milestone payment from Pfizer following the start of a Phase I clinical trial of Pfizer drug candidate PF-06755347, previously known as GL-2045, for the potential treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder. Gliknik and Pfizer entered into an exclusive worldwide licensing agreement in 2013.   “Beginning the Phase I clinical trial is an important milestone in the development of this drug candidat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters